Tag: investors

ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL) complied with federal securities laws. On July 22, 2025, Replimune announced it received a Complete Response Letter (“CRL”) from the FDA regarding the Biologics License Application (“BLA”) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. In the CRL, the FDA indicated “that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.” Following this news, the price of the Company’s stock dropped. 

IRVINE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- ECGI Holdings Inc. (OTC: ECGI), a diversified holding company focused on innovation and growth, today announced that its investment arm, Uplist Ventures, was accepted as an affiliate member of TCA Venture Group (formerly Tech Coast Angels). This move positions Uplist Ventures to access one of the most active angel investor networks in the United States, providing exclusive visibility into high-quality early- and growth-stage opportunities.

Paris, July 22^nd, 2025

WOODLAND PARK, N.J., July 22, 2025 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) announced today that it will hold a conference call on Wednesday, August 13, 2025, at 9:00 a.m. ET. Anterix senior management, led by President and CEO Scott Lang, will discuss the Company's first quarter fiscal 2026 results. A press release regarding the results will be issued after the close of the market on Tuesday, August 12, 2025.

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com

New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.